APOE and Alzheimer disease: For instance, a reduced n-3/n-6 PUFA ratio, along with decreased levels of the DHA-derived neuroprotectin D1 and activated eicosanoid signaling, is observed in the brains of AD patients—particularly in APOE4 carriers—suggesting a state of chronic inflammation.